SRNE News and Press, Sorrento Therapeutics Inc. From 11/23/20

In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , highlights what investors should expect from the biotech's COVID-19 products in months ahead. Ji also talks about the company's financial sit...

Sorrento Therapeutics (NASDAQ: SRNE) arguably has the most diverse set of products for the COVID-19 pandemic. In this video from Motley Fool Live recorded on Nov. 12, executives from the company talk about a few of the biotech's preclinical products. Salicyn 30 is an an...

Sorrento Therapeutics (NASDAQ: SRNE) has taken a broad approach to developing tests, treatments, and vaccines for COVID-19. In the process, the biotech certainly hasn't broken any biotech speed records and trails the leaders in each of the three categories. Nevertheless, in this...

Sorrento Therapeutics (NASDAQ: SRNE) is considerably behind Pfizer (NYSE: PFE) , BioNTech (NASDAQ: BNTX) , Moderna (NASDAQ: MRNA) , and the rest of the leaders in the race to develop a coronavirus vaccine. While multiple vaccines have completed phase 3 clinic...

In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about the company's second-generation therapeutic antibody. An investigational new drug (IND) application has been submitted to the Food and Drug Administration. ...

In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks with host Brian Orelli about how better-designed neutralizing antibodies can still make an impact in the crowded COVID-19 treatment and...

In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) discuss the company's therapeutic antibodies to treat COVID-19, the disease caused by the novel coronavirus. Mark Brunswick, senior vice president of regulatory affa...

In this video from Motley Fool Live recorded on Nov. 12, Sorrento Therapeutics ' (NASDAQ: SRNE) chairman, president, and CEO Henry Ji and senior vice president of regulatory affairs Mark Brunswick discuss the company's three COVID-19 tests. None of the tests have gained an Emerg...

In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about how the company's COVID-19 therapeutic antibodies -- STI-1499 and STI-2020 -- can coexist with the coronavirus vaccines. Since the recording, both Moder...

In this video from Motley Fool Live , which was recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks about how the biotech got its start. The company's focus on antibodies has helped it pivot from a previous focus on de...